[go: up one dir, main page]

AR050958A1 - BICYCLE ANTIBIOTICS - Google Patents

BICYCLE ANTIBIOTICS

Info

Publication number
AR050958A1
AR050958A1 ARP050104029A ARP050104029A AR050958A1 AR 050958 A1 AR050958 A1 AR 050958A1 AR P050104029 A ARP050104029 A AR P050104029A AR P050104029 A ARP050104029 A AR P050104029A AR 050958 A1 AR050958 A1 AR 050958A1
Authority
AR
Argentina
Prior art keywords
ch2ch2
ch2ch
nhco
alkyl
och2
Prior art date
Application number
ARP050104029A
Other languages
Spanish (es)
Original Assignee
Actelion Percurex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Percurex Ag filed Critical Actelion Percurex Ag
Publication of AR050958A1 publication Critical patent/AR050958A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicacion 1: Un compuesto seleccionado desde el grupo consistente de un compuesto de la formula (1) donde R1 representa un alquil, alcoxi, haloalcoxi, halogeno o ciano; uno o dos de U, V, W y X representa(n) N, el resto representa CH, o, en el caso de U, V y/o W, puede también representar CRa y, en el caso de X, puede también representar CRb; Ra representa halogeno; Rb representa un halogeno o alcoxi; D representa un alquil, aril o heteroaril; M es seleccionado desde el grupo consistente de M1, M2, M3 y M4; M1 donde A1 representa NHCO, OCH2, CH2CH2, CH=CH o CH(OH)CH2; A2 representa NHCH2, NHCO, NHCH2CONH, NHCH2CH=CH, CH2CH2, CH2CO, COCH2, CH2CH(OH) o CH2CH(OCONH2); B1 y B2 cada uno representa independientemente cada uno del otro N o CH; cuando A1 representa OCH2, B1 representa CH; n es 1; o n es también 0 cuando B1 es CH; y p es 1; o p es también 0 cuando B2 es CH; M2 donde A3 representa NHCO, CH2CH2, CH=CH, COCH2, CH(OH)CH2, CH2CH(OH), CH(OH)CH(OH) o OCH2; A4 representa CH2, CO, CH2CH=CH, COCH=CH o CH2CONH; R2 representa H, alquil, hidroxialquil, alquilcarboniloxialquil, carbamoiloxialquil, carboxialquil o carbamoilalquil; R3 y R4 cada uno independientemente representa H, hidroxi o alquilcarboniloxi; o R3 y R4 juntos representan union de cadena dimetilmetilenodioxi unida a carbonos de apoyo de carbonos de R3 y R4; R5 representa H alquil o hidroxialquil; y la doble línea representa un enlace simple o, cuando R3 y r4 representan H, también representa un doble enlace; M3 donde A5 representa CH2CH2, CH=CH, COCH2, CH(OH)CH2, NHCO(CH2)m, NHCOCH2O, NHCOOCH2 o O(CH2)q; m es 0, 1 o 2; q es 1, 2 o 3 y B6 representa N y A6 representa CH2, CH2CH2, CH2CH=CH o CH2CH2S; o B6 representa CH y A6 representa CH2NHCH2, CH2NHCH2CONH o CH2NHCH2CH=CH; M4 donde A7 representa NHCO, CH2CH2 o OCH2; A8 representa CH2; y R6 representa H o alquil; y una prodroga, un tautomero, un enantiomero optimamente puro, una mezcla de enantiomeros, un racemato, un diastereoisomero optimamente puro, una mezcla de diastereoisomeros, un racemato diastereoisomérico, mezcla de racematos diastereoisoméricos, una meso-forma, una forma morfologica, una sal o un complejo solvente de tal compuesto.Claim 1: A compound selected from the group consisting of a compound of the formula (1) wherein R 1 represents an alkyl, alkoxy, haloalkoxy, halogen or cyano; one or two of U, V, W and X represents (n) N, the rest represents CH, or, in the case of U, V and / or W, may also represent CRa and, in the case of X, may also represent CRb; Ra represents halogen; Rb represents a halogen or alkoxy; D represents an alkyl, aryl or heteroaryl; M is selected from the group consisting of M1, M2, M3 and M4; M1 where A1 represents NHCO, OCH2, CH2CH2, CH = CH or CH (OH) CH2; A2 represents NHCH2, NHCO, NHCH2CONH, NHCH2CH = CH, CH2CH2, CH2CO, COCH2, CH2CH (OH) or CH2CH (OCONH2); B1 and B2 each independently represents each other's N or CH; when A1 represents OCH2, B1 represents CH; n is 1; or n is also 0 when B1 is CH; and p is 1; or p is also 0 when B2 is CH; M2 where A3 represents NHCO, CH2CH2, CH = CH, COCH2, CH (OH) CH2, CH2CH (OH), CH (OH) CH (OH) or OCH2; A4 represents CH2, CO, CH2CH = CH, COCH = CH or CH2CONH; R2 represents H, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, carbamoyloxyalkyl, carboxyalkyl or carbamoylalkyl; R3 and R4 each independently represents H, hydroxy or alkylcarbonyloxy; or R3 and R4 together represent dimethylmethylenedioxy chain bonding to carbon support carbons of R3 and R4; R5 represents H alkyl or hydroxyalkyl; and the double line represents a single bond or, when R3 and r4 represent H, it also represents a double bond; M3 where A5 represents CH2CH2, CH = CH, COCH2, CH (OH) CH2, NHCO (CH2) m, NHCOCH2O, NHCOOCH2 or O (CH2) q; m is 0, 1 or 2; q is 1, 2 or 3 and B6 represents N and A6 represents CH2, CH2CH2, CH2CH = CH or CH2CH2S; or B6 represents CH and A6 represents CH2NHCH2, CH2NHCH2CONH or CH2NHCH2CH = CH; M4 where A7 represents NHCO, CH2CH2 or OCH2; A8 represents CH2; and R6 represents H or alkyl; and a prodrug, a tautomer, an optimally pure enantiomer, a mixture of enantiomers, a racemate, an optimally pure diastereoisomer, a mixture of diastereoisomers, a diastereoisomeric racemate, mixture of diastereoisomeric racemates, a meso-form, a morphological form, a salt or a solvent complex of such a compound.

ARP050104029A 2004-09-24 2005-09-26 BICYCLE ANTIBIOTICS AR050958A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2004010762 2004-09-24
EP2005007731 2005-07-15

Publications (1)

Publication Number Publication Date
AR050958A1 true AR050958A1 (en) 2006-12-06

Family

ID=36090370

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104029A AR050958A1 (en) 2004-09-24 2005-09-26 BICYCLE ANTIBIOTICS

Country Status (5)

Country Link
JP (1) JP4887297B2 (en)
AR (1) AR050958A1 (en)
CA (1) CA2580621A1 (en)
TW (1) TW200615267A (en)
WO (1) WO2006032466A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709472B2 (en) 2005-01-25 2010-05-04 Glaxo Group Limited Antibacterial agents
RU2007147413A (en) * 2005-05-24 2009-06-27 Астразенека Аб (Se) AMINOPIPERIDINCHINOLINS AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
CN101374831B (en) 2006-01-26 2011-04-27 埃科特莱茵药品有限公司 tetrahydropyran antibiotics
EP1987040B1 (en) 2006-02-15 2010-11-10 Actelion Pharmaceuticals Ltd. Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
CA2643962A1 (en) * 2006-03-10 2007-09-20 Actelion Pharmaceuticals Ltd Antibiotic compounds
WO2007115947A1 (en) 2006-04-06 2007-10-18 Glaxo Group Limited Pyrrolo-quinoxalinone derivatives as antibacterials
EP2044059A1 (en) * 2006-06-08 2009-04-08 Speedel Experimenta AG 2,5-disubstituted piperidines
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
TW200819457A (en) 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
CL2007003693A1 (en) * 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd COMPOUNDS DERIVED FROM PIRIDO [3,2-B] [1,4] THIAZINE; PHARMACEUTICAL COMPOSITION CONTAINING SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF BACTERIAL INFECTIONS.
CL2008001002A1 (en) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd COMPOUNDS DERIVED FROM OXAZOLIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT A BACTERIAL INFECTION.
CL2008001003A1 (en) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd COMPOUNDS DERIVED FROM OXAZOLIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT A BACTERIAL INFECTION.
MY149347A (en) 2007-04-20 2013-08-30 Glaxo Group Ltd Tricyclic nitrogen containing compounds as antibacterial agents
ES2370123T3 (en) * 2007-06-15 2011-12-12 Actelion Pharmaceuticals Ltd. DERIVATIVES OF 3-AMINO-6- (1-AMINOETIL) -TETRAHYDROPIRANE.
EP2005995A1 (en) * 2007-06-22 2008-12-24 Glaxo Group Limited Heterocyclic compounds for the treatment of tuberculosis
CA2706837C (en) 2007-12-18 2016-05-03 Actelion Pharmaceuticals Ltd 5-aminocyclylmethyl-oxazolidin-2-one derivatives
EP2080761A1 (en) 2008-01-18 2009-07-22 Glaxo Group Limited Compounds
CA2713182C (en) 2008-02-20 2016-09-13 Actelion Pharmaceuticals Ltd Azatricyclic antibiotic compounds
JP2011518149A (en) 2008-04-15 2011-06-23 アクテリオン ファーマシューティカルズ リミテッド Tricyclic antibacterial agent
RU2515906C2 (en) 2008-06-03 2014-05-20 Актелион Фармасьютиклз Лтд [4-(1-aminoethyl)cyclohexyl]methylamine and [6-(1-aminoethyl)tetrahydropyran-3-yl]methylamine derivatives
KR20110036938A (en) 2008-08-04 2011-04-12 액테리온 파마슈티칼 리미티드 Tricyclic Alkylaminomethyloxazolidinone Derivatives
DK2344495T3 (en) 2008-10-07 2015-02-02 Actelion Pharmaceuticals Ltd TRICYCLIC OXAZOLIDINON ANTIBIOTIC COMPOUNDS
WO2010043714A1 (en) 2008-10-17 2010-04-22 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials
US8642629B2 (en) 2008-11-17 2014-02-04 Hoffmann-La Roche Inc. Naphthylacetic acids
RU2525541C2 (en) 2008-12-12 2014-08-20 Актелион Фармасьютиклз Лтд 5-amino-2-(1-hydroxyethyl)tetrahydropyran derivatives
US8318940B2 (en) 2009-01-15 2012-11-27 Glaxo Group Limited Naphthyridin-2 (1 H)-one compounds useful as antibacterials
AU2010206161B2 (en) 2009-01-21 2014-08-07 Basilea Pharmaceutica Ag Novel bicyclic antibiotics
AR076222A1 (en) 2009-04-09 2011-05-26 Actelion Pharmaceuticals Ltd DERIVATIVES 2-HYDROXIETIL-1H-QUINOLIN-ONA AND ITS AZAISOTHERAL ANALOGS WITH ANTIBACTERIAL ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
CA2829188C (en) 2011-03-10 2016-10-18 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivatives
WO2012125661A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists
CA2780403C (en) * 2011-06-17 2020-04-21 Forest Laboratories Holdings Ltd. Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
US20140243302A1 (en) * 2011-06-27 2014-08-28 Merck Sharp & Dohme Corporation Bridged bicyclic compounds for the treatment of bacterial infections
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
US9029368B2 (en) 2011-11-30 2015-05-12 Actelion Pharmaceuticals Ltd. 3,7-disubstituted octahydro-2H-pyrido[4,3-E][1,3]oxazin-2-one antibiotics
SG11201700566SA (en) 2014-08-22 2017-03-30 Glaxosmithkline Ip Dev Ltd Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection
TW201722965A (en) 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 Compounds for use in antibacterial applications
CA3072057A1 (en) * 2017-09-01 2019-03-07 Denali Therapeutics Inc. Small molecule modulators of eukaryotic initiation factor 2b
WO2019054427A1 (en) 2017-09-14 2019-03-21 第一三共株式会社 Compound having cyclic structure
CN109082280B (en) * 2018-11-05 2020-07-28 宁夏中星显示材料有限公司 Preparation method of liquid crystal material
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
JP4445753B2 (en) * 2002-01-29 2010-04-07 グラクソ グループ リミテッド Aminopiperidine derivatives
TW200406413A (en) * 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
TW200409637A (en) * 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
JP4602903B2 (en) * 2002-10-10 2010-12-22 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー New compounds with antibacterial activity
DE10256405A1 (en) * 2002-12-02 2004-06-17 Morphochem Aktiengesellschaft für kombinatorische Chemie New 4-substituted quinoline derivatives, useful for treating bacterial infections, optionally including additional ring nitrogens
DE10316081A1 (en) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie New compounds with antibacterial activity
WO2006012396A1 (en) * 2004-07-22 2006-02-02 Glaxo Group Limited Antibacterial agents
DE102004041163A1 (en) * 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie New compounds with antibacterial activity

Also Published As

Publication number Publication date
JP4887297B2 (en) 2012-02-29
WO2006032466A2 (en) 2006-03-30
JP2008514563A (en) 2008-05-08
WO2006032466A3 (en) 2006-12-14
CA2580621A1 (en) 2006-03-30
TW200615267A (en) 2006-05-16

Similar Documents

Publication Publication Date Title
AR050958A1 (en) BICYCLE ANTIBIOTICS
IN2015DN01133A (en)
RU98106623A (en) DITIOLANE DERIVATIVES, THEIR PRODUCTION AND THERAPEUTIC EFFECT
NZ543186A (en) Reverse-turn mimetics and method relating thereto
CA2545427A1 (en) Selective kinase inhibitors
WO2022261240A3 (en) Dimethoxyphenylalkylamine activators of serotonin receptors
RU2003132687A (en) TREATMENT OF TYPE 2 DIABETES BY DIPEPTIDYLPEPTIDASE IV INHIBITORS
CO5680403A2 (en) MCHR1R ANTAGONISTS
UY27357A1 (en) NEW ANTIDIABETIC AGENTS.
CA2497868A1 (en) Heterocyclic compounds
AR066012A1 (en) OXAZOLIDINONE DERIVATIVES, MEDICINAL, PHARMACEUTICAL COMPOSITION AND USE IN BACTERIAL INFECTIONS
JP2002522536A5 (en)
AR033379A1 (en) DIFENILUREA COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR042658A1 (en) DERIVATIVES OF 1,5-DIARIL-PIRROL-3-CARBOXAMIDE AND ITS USE AS CANABINOID RECEIVER MODULATORS
NO20033145D0 (en) Purine derivatives as purinergic receptor antagonists
RU2008141850A (en) LIQUID PHARMACEUTICAL PRODUCT WITH IMMEDIATE RELEASE
EA200500690A1 (en) NEW PYRIDOPYRIMIDINON COMPOUNDS, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
SE0101579D0 (en) New compounds
EA200700901A1 (en) DERIVATIVES 2-AMIDO-4-PHENYL THIAZOLE, THEIR OBTAINING AND USE IN THERAPY
AR053554A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
AR044830A1 (en) DERIVATIVES OF 4,5 DIARIL -3-HETEROCICLILPIRAZIN- 2- ESTER
AR069800A1 (en) DERIVATIVES 5- AMINOCICLILMETIL - OXAZOLIDIN-2- ONA
PE20070325A1 (en) ORAL DOSAGE FORMS THAT INCLUDE CARBAMATE-DERIVED COMPOUNDS
CO5261622A1 (en) INHIBITORS OF PROTEINASE C OF PROCOLAGEN
EA200800502A1 (en) 3-AMINOCARBAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THE INDICATED COMPOUNDS, AND METHOD FOR THEIR PRODUCTION

Legal Events

Date Code Title Description
FB Suspension of granting procedure